Leibovit-Reiben Z, Godfrey H, Jedlowski P, Thiede R, et al. Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Melanoma Res 2024 Dec 6. doi: 10.1097/CMR.0000000000001015.
PMID: 39656586